Board of Directors

Douglas Le Fort

Non-executive Chairman

Douglas was appointed as a Non-executive Director of Advanced Medical Solutions in August 2021. He is currently an Operating Partner for Revival Healthcare Capital Partners, an investor in medical device and diagnostics businesses, as well as a Non-executive Director at Trio Healthcare, a manufacturer of ostomy products, Clinisupplies, a UK based manufacturer of chronic care products and “The Insides” Company Ltd, a start-up addressing intestinal failure based in New Zealand.

Douglas is a seasoned veteran in the medical and life science industry, with more than 20 years of senior executive leadership. He has expertise in business strategy, including commercial business execution, operational management and M&A. Most recently, he was CEO of MedTrade Products, a woundcare products business and prior to that served in various senior executive roles at ConvaTec Group plc, including five years on the Executive Committee for the Group. At ConvaTec he was Senior Vice President for Corporate Development, and prior to that Vice President and General Manager with P&L responsibility for the global Ostomy business. Douglas has an MBA from Henley Management College and is a Chartered Management Accountant.

Dr Michael Griffiths

Chief Executive Officer

Mike is a seasoned medical device executive who has been the CEO, President and Co-Founder of AOTI Inc. since 2006. He brings with him over 35 years of experience gained from a wide variety of management roles throughout the globe, working with both start-ups and multinationals alike. Prior to joining AOTI, Mike was the co-founder and CEO of eVent Medical Ltd., a start-up venture in the critical care ventilation field, which was sold to the Kobayashi Pharmaceutical Company of Japan. Preceding eVent, Mike held various senior management positions at Mallinckrodt Inc., Nellcor Puritan Bennett Inc., and Hudson RCI, amongst others.

Mike is a Fellow of both the Royal Society of Medicine and Chartered Management Institute. He holds a Doctorate in Medical Device Innovation and Entrepreneurship from Middlesex University, London, United Kingdom, a post-graduate Diploma in Management from Kingston University, United Kingdom, and several further engineering and clinical credentials, including that of a Certified Respiratory Therapist. Mike is also an active advocate in achieving mental health equity as the Chairman of the International Bipolar Foundation.

Anthony Moffatt

Chief Operating Officer

Anthony joined AOTI in January of 2009 as Director of Finance and Customer Service. Up until June 2024, he served as the company’s CFO and Vice President of Customer Service, overseeing both the USA and Irish finances and back-office functions for the company. From June 2024, he is serving as Chief Operating Officer and the Chief Financial Officer role has transitioned to Jayesh Pankhania. Prior to AOTI, Anthony spent 5 years as Financial Controller of eVent Medical Ltd and helped deliver a substantial return to investors. He also worked for a number of years in an accounting practice in Dublin. Anthony has a degree in business studies and is a qualified ACCA accountant.

Jayesh Pankhania

Chief Financial Officer

Jayesh joined AOTI as Chief Financial Officer in June 2024. Prior to joining AOTI, Jayesh served as the Chief Financial Officer of CONGENICA Limited from April 2021, an early stage genomic diagnostic business, and Chief Financial Officer of Horizon Discovery Group PLC, an AIM listed life sciences business, from April 2018 to March 2021. Prior to that Jayesh spent his career in numerous other senior Chief Financial Officer and other finance roles in a broad range of small and large businesses. Jayesh is a Fellow of the Institute of Chartered Accountants in England and Wales, holds an MBA from London Business School and a BSc in Accountancy from the University of East Anglia.

Anthony (Tony) Bourne

Non-executive Director

Tony’s 40 year career includes 25 years in investment banking in London and New York, 9 years as CEO of the British Medical Association and latterly as a NED on the boards of a number of listed and non-listed companies, mostly in the healthcare sector.

Tony is currently Chair of the Chelsea and Westminster Health Charity (now called CW+), one of the largest NHS charities, where he is also a member of the Finance & Investment Committee as well as a member of the Innovation Advisory Board. He is a NED of Barchester, the second largest owner and operator of care homes in the UK where he was also a member of the Audit and Investment Committees; Totally plc, an AIM-quoted leader in urgent and planned healthcare where he Chairs the Remuneration and Nominations Committees; and, until recently, served as a NED of Spire Healthcare plc for 9 years where he was Chair of the Remuneration Committee and member of the Audit and Risk, and Clinical Governance and Safety Committees. Tony was previously Chair of Universal Engineering Holdings and a NED at Southern Housing Group and Bioquell plc.

Dr Ceri Morgan

Non-executive Director

Ceri began her career in medicine and held various positions at Queen Elizabeth Hospital in Birmingham and Addenbrookes Hospital in Cambridge where she was part of the Casualty and Trauma Department’s first response unit.

After leaving medicine in 2001, Ceri joined Beeson Gregory as a healthcare and life science research analyst before changing roles. Ceri was a key founder of the healthcare and life science franchise at Peel Hunt, where the team was ranked top by institutional investors for several years. She moved to Numis Securities where, as a #1 Extel-ranked specialist salesperson, she led on numerous IPOs and capital raises. In 2021, Ceri joined Oxford Science Enterprises as Head of Late Stage Portfolio where she managed investments and advised on key listings including PepGen’s NASDAQ listing. Ceri serves as a Non-executive Director for Syniad Innovations and holds a Senior Advisor position at LifeScience ORG.

Richard Cotton

Senior Independent Director

Richard has a wealth of experience in non-executive director, advisory and senior financial roles in life sciences and other industrial sectors. His extensive experience covers all the value creation activities from R&D, to manufacturing and commercial in international organisations. He has significant experience in the development and successful execution of strategy, corporate finance and M&A, capital markets and governance.

Currently Richard is Chair at Nasdaq listed AI predictive diagnostics company Spectral AI, and is also Financial Adviser at Novumgen Ltd., a Specialty Pharmaceuticals company. His prior executive roles include highly successful tenures as CFO at FTSE250 animal health company Dechra Pharmaceuticals plc, and as CFO at medical device and drug formulation business Consort Medical plc.

Fellow of the Chartered Institute of Management Accountants, Mr. Cotton holds a BA (Hons) in Business Studies from Kingston University.